![](https://library.celltelligence.com/wp-content/uploads/2021/04/Bluebird_BMS-Clinical-Trials.png)
$0
Thoughts on BMS’s New Abecma Ph1/2 KarMMa-7 Basket Combination Trial
On Thursday, April 22, a new Abecma (BCMA CAR-T) Ph1/2 combinational trial (KarMMa-7) for the treatment of r/r MM was observed on CT.gov. Below, Celltelligence provides insights on how BMS could strategically leverage the Ph1/2 KarMMa-7 trial to improve Abecma’s efficacy while investigating several fully owned compounds to disrupt the current SOC regimens for r/r MM.